Verified Nov 2026
Other
·

Chicago, Illinois
·
Since 1867
Mallinckrodt is a specialty pharmaceutical company founded in 1867 and headquartered in Chicago, Illinois, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops and manufactures branded specialty pharmaceuticals, generic drugs, active pharmaceutical ingredients, and medical imaging products for autoimmune, rare, and neonatal respiratory conditions. In 2025, the company completed a merger with Endo and a subsequent spin-off, establishing Keenova Therapeutics as its specialty therapeutics platform.
Mallinckrodt at a glance
Revenue
$1-5B
Est. band
Employees
1,000-5,000
Founded
1867
Headquarters
Chicago, Illinois
Certifications
ISO 13485
Import activity
1408
Industries
Automotive
Electric Vehicles
Medical
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
1408
Named foreign suppliers
41
Top origins
Italy · India · Netherlands · Canada

Shared foreign counterparties do not establish that these companies buy from Mallinckrodt.
What this tells a buyer
The company received approximately 1,408 shipments, with 1,252 originating from its Irish subsidiary and additional supply routes spanning 16 countries including India, Canada, Italy, and the United Kingdom.
Mallinckrodt holds ISO 13485 certification and produces specialty pharmaceuticals, generics, active pharmaceutical ingredients, medical imaging products including technetium-99m for nuclear medicine, and pain management formulations.
The company serves physicians, specialty pharmacies, hospitals, and retail pharmacy chains with treatments for pain management, ADHD, and complex medical conditions across automotive, electric-vehicle, and medical industries.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Established & active
159 years in operation (founded 1867).
1,408 US import shipments on record.
Holds ISO 13485 certification(s) per public sources.
Overview
Mallinckrodt is a specialty pharmaceutical company founded in 1867 and headquartered in Chicago, Illinois, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops and manufactures branded specialty pharmaceuticals, generic drugs, active pharmaceutical ingredients, and medical imaging products for autoimmune, rare, and neonatal respiratory conditions. In 2025, the company completed a merger with Endo and a subsequent spin-off, establishing Keenova Therapeutics as its specialty therapeutics platform.
At a glance
Attribute | Detail |
|---|---|
Founded | 1867 |
Headquarters | Chicago, Illinois |
Employees | 1,000-5,000 |
Revenue | $1-5B (estimated) |
Certifications | ISO 13485 |
What Mallinckrodt makes
Mallinckrodt holds ISO 13485 certification and produces specialty pharmaceuticals, generics, active pharmaceutical ingredients, medical imaging products including technetium-99m for nuclear medicine, and pain management formulations.
Certifications
Mallinckrodt is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 13485 — prnewswire.com
Trade and customs footprint
The company received approximately 1,408 shipments, with 1,252 originating from its Irish subsidiary and additional supply routes spanning 16 countries including India, Canada, Italy, and the United Kingdom. US customs bill-of-lading records list 1408 inbound shipments across 41 foreign suppliers, with top origins including Italy · India · Netherlands · Canada.
Latest developments
2025-11-11 — Mallinckrodt, Endo become Keenova following generics spinoff (fiercepharma.com)
2025-11-10 — Mallinckrodt Reports Third Quarter 2025 Financial Results | Keenova (mallinckrodt.com)
2025-11-10 — Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics (advfn.com)
2025-10-22 — Maine DEP Takes Further Action Against Mallinckrodt US LLC/Medtronic for Compliance Issues
, Maine DEP Media Release (maine.gov)2025-08-01 — Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader | Keenova (mallinckrodt.com)
2025-03-13 — Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader | Keenova (mallinckrodt.com)
Company details
The company serves physicians, specialty pharmacies, hospitals, and retail pharmacy chains with treatments for pain management, ADHD, and complex medical conditions across automotive, electric-vehicle, and medical industries. Mallinckrodt was founded in 1867, has an estimated 1,000-5,000 employees, and is headquartered in Chicago, Illinois. On the LightSource stability read it is rated "Established & active": 159 years in operation (founded 1867). 1,408 US import shipments on record. Holds ISO 13485 certification(s) per public sources.
Frequently asked questions
What does Mallinckrodt do?
Mallinckrodt is a specialty pharmaceutical company founded in 1867 and headquartered in Chicago, Illinois, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops and manufactures branded specialty pharmaceuticals, generic drugs, active pharmaceutical ingredients, and medical imaging products for autoimmune, rare, and neonatal respiratory conditions. In 2025, the company completed a merger with Endo and a subsequent spin-off, establishing Keenova Therapeutics as its specialty therapeutics platform.
Where is Mallinckrodt headquartered?
Mallinckrodt is headquartered in Chicago, Illinois.
When was Mallinckrodt founded?
Mallinckrodt was founded in 1867.
How big is Mallinckrodt?
Mallinckrodt has an estimated 1,000-5,000 employees, with revenue in the $1-5B range (estimated).
What certifications does Mallinckrodt hold?
Mallinckrodt lists ISO 13485 on its website. Confirm the certified scope for the specific plant producing your part.
Does Mallinckrodt import from overseas suppliers?
US customs bill-of-lading records show 1408 inbound shipments for Mallinckrodt, with top origins including Italy · India · Netherlands · Canada.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
